The present invention relates to a pharmaceutical composition comprising a liquid composition containing p-boronophenylalanine, in which the liquid composition is accommodated in a packaging material and satisfies the following Condition I or Condition II: Condition I: the liquid composition comprises substantially no antioxidant and a concentration of dissolved oxygen in the liquid composition is 3.5 ppm or less; Condition II: the liquid composition comprises an antioxidant and a concentration of dissolved oxygen in the liquid composition is 3.0 ppm or less.

Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. The subject methods include modifying donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

Methods of sterilizing biologics or biological components are disclosed wherein the biologic or biological component in solution or suspension form are formed using an annealing step during freeze drying so that a porous solid matrix which allows penetration of a sterilizing gas such as EtO to pass through. The annealing process decreases the particle size of lyophilized material as compared to other methods and provides a more uniform cake that is easy to reconstitute. In addition, the resulting lyophilized material made with the annealing step allows better penetration of the sterilizing gas for more effective and uniform sterilization of the material.

Methods of sterilizing biologics or biological components are disclosed wherein the biologic or biological component in solution or suspension form are formed using an annealing step during freeze drying so that a porous solid matrix which allows penetration of a sterilizing gas such as EtO to pass through. The annealing process decreases the particle size of lyophilized material as compared to other methods and provides a more uniform cake that is easy to reconstitute. In addition, the resulting lyophilized material made with the annealing step allows better penetration of the sterilizing gas for more effective and uniform sterilization of the material.

A plasma activated ophthalmic solution generating device operable to generate a therapeutic ophthalmic solution for curing epidemic keratoconjunctivitis includes a plasma generating electrode operable to generate a plasma activated ophthalmic solution for epidemic keratoconjunctivitis, wherein the plasma generating electrode is arranged surrounding an insert space where a unit dose ophthalmic eyedrop container with a container body, which seals a certain solution in a sterile state, is inserted; a power supply unit; and a high voltage generating unit, which is connected to the power supply unit, operable to be supplied with power source from the power supply unit and to apply high voltage electric current to the plasma generating electrode. This configuration makes it possible to provide a novel and effective therapeutic ophthalmic solution for epidemic keratoconjunctivitis (EKC).

A plasma activated ophthalmic solution generating device operable to generate a therapeutic ophthalmic solution for curing epidemic keratoconjunctivitis includes a plasma generating electrode operable to generate a plasma activated ophthalmic solution for epidemic keratoconjunctivitis, wherein the plasma generating electrode is arranged surrounding an insert space where a unit dose ophthalmic eyedrop container with a container body, which seals a certain solution in a sterile state, is inserted; a power supply unit; and a high voltage generating unit, which is connected to the power supply unit, operable to be supplied with power source from the power supply unit and to apply high voltage electric current to the plasma generating electrode. This configuration makes it possible to provide a novel and effective therapeutic ophthalmic solution for epidemic keratoconjunctivitis (EKC).

Infectious diseases can be transmitted to humans, or between humans and animals, by airborne viruses and bacteria, known as infectious aerosols. Current protective measures that individuals can take to avoid inhaling such aerosols are either marginally effective (personal face masks) or impractical (self-contained breathing apparatuses). Building ventilation systems employing high-efficiency filters to prevent distribution of such aerosols suffer from high energy costs and high filter replacement costs. The development of conventional, intramuscularly administered vaccines takes months or years to produce enough doses to protect a population from a rapidly spreading infectious disease. Airborne viruses and bacteria have been shown to be completely inactivated when exposed to non-thermal plasmas. Results indicate the potential for sub-lethal exposures of airborne pathogens could render them unable to spark an infection in a host, but still retain the necessary surface proteins to cause an immune response in the host.

Infectious diseases can be transmitted to humans, or between humans and animals, by airborne viruses and bacteria, known as infectious aerosols. Current protective measures that individuals can take to avoid inhaling such aerosols are either marginally effective (personal face masks) or impractical (self-contained breathing apparatuses). Building ventilation systems employing high-efficiency filters to prevent distribution of such aerosols suffer from high energy costs and high filter replacement costs. The development of conventional, intramuscularly administered vaccines takes months or years to produce enough doses to protect a population from a rapidly spreading infectious disease. Airborne viruses and bacteria have been shown to be completely inactivated when exposed to non-thermal plasmas. Results indicate the potential for sub-lethal exposures of airborne pathogens could render them unable to spark an infection in a host, but still retain the necessary surface proteins to cause an immune response in the host.

The present disclosure relates to compositions comprising a non-viable fecal bacterial preparation for treating various gastrointestinal-related conditions and disorders. The present disclosure also relates to stool-based compositions comprising adjuvants to facilitate the efficacy of immunomodulators such as vaccines and immunotherapies.

The present disclosure relates to compositions comprising a non-viable fecal bacterial preparation for treating various gastrointestinal-related conditions and disorders. The present disclosure also relates to stool-based compositions comprising adjuvants to facilitate the efficacy of immunomodulators such as vaccines and immunotherapies.